{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33443"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33443","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Advancing Outcome Measurement in Refractory or Unexplained Chronic Cough","abstract":"Refractory or unexplained chronic cough (RCC/UCC) is a debilitating condition that substantially impacts patients’ quality of life. No licensed therapies exist in Canada, and suboptimal clinical trial endpoints, coupled with large placebo responses, have hindered drug development. This thesis advances outcome measurement in RCC/UCC to improve the detection and interpretation of treatment effects. To characterize drug efficacy and placebo responses, we conducted a dose-response meta-analysis of gefapixant, the first P2X3 antagonist to reach phase 3 trials. This analysis quantified gefapixant’s modest efficacy and confirmed a substantial placebo response. To better understand this response and inform future trial designs, we described underlying neurobiological mechanisms as well as non-specific contributors, including regression-to-the-mean and patient expectancy. During review of the gefapixant development program, major regulatory agencies emphasized the need for outcome measures that better capture patient-important benefits and meet fit-for-purpose standards. We thus developed and evaluated the McMaster Cough Severity Questionnaire (MCSQ), an 8-item patient-reported outcome measure comprising two domains and a one-week recall period. Using mixed methods, classical test theory, and Rasch modelling, we demonstrated the MCSQ’s strong content validity, construct validity, and test-retest reliability, supporting its use as a promising endpoint for future clinical trials. To illustrate its application, we designed a 2x2 factorial randomized trial protocol evaluating the comparative effectiveness and harms of two commonly prescribed neuromodulators, low-dose morphine and pregabalin, and a non-pharmacologic intervention, cough control therapy, for RCC/UCC. This trial will further evaluate the MCSQ’s longitudinal validity, responsiveness, and minimal important differences. Collectively, this work strengthens the methodological foundation for clinical trials in RCC/UCC and supports more patient-centered evaluation of emerging therapies.","abstract_html":"Refractory or unexplained chronic cough (RCC/UCC) is a debilitating condition that substantially impacts patients’ quality of life. No licensed therapies exist in Canada, and suboptimal clinical trial endpoints, coupled with large placebo responses, have hindered drug development. This thesis advances outcome measurement in RCC/UCC to improve the detection and interpretation of treatment effects. To characterize drug efficacy and placebo responses, we conducted a dose-response meta-analysis of gefapixant, the first P2X3 antagonist to reach phase 3 trials. This analysis quantified gefapixant’s modest efficacy and confirmed a substantial placebo response. To better understand this response and inform future trial designs, we described underlying neurobiological mechanisms as well as non-specific contributors, including regression-to-the-mean and patient expectancy. During review of the gefapixant development program, major regulatory agencies emphasized the need for outcome measures that better capture patient-important benefits and meet fit-for-purpose standards. We thus developed and evaluated the McMaster Cough Severity Questionnaire (MCSQ), an 8-item patient-reported outcome measure comprising two domains and a one-week recall period. Using mixed methods, classical test theory, and Rasch modelling, we demonstrated the MCSQ’s strong content validity, construct validity, and test-retest reliability, supporting its use as a promising endpoint for future clinical trials. To illustrate its application, we designed a 2x2 factorial randomized trial protocol evaluating the comparative effectiveness and harms of two commonly prescribed neuromodulators, low-dose morphine and pregabalin, and a non-pharmacologic intervention, cough control therapy, for RCC/UCC. This trial will further evaluate the MCSQ’s longitudinal validity, responsiveness, and minimal important differences. Collectively, this work strengthens the methodological foundation for clinical trials in RCC/UCC and supports more patient-centered evaluation of emerging therapies.","abstract_has_math":false,"creators":["Kum, Elena"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Health Research Methodology","school":null,"contributors":[],"advisors":["Satia, Imran"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:38:51Z","subjects":["Chronic cough","Cough","Refractory Chronic Cough","Unexplained Chronic Cough"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/2227"],"render_values":[{"text":"https://doi.org/10.71548/2227","href":"https://doi.org/10.71548/2227","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33443","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33443","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33443","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Satia, Imran"]},{"key":"dc:contributor.department","label":"Department","values":["Health Research Methodology"]},{"key":"dc:creator","label":"Author","values":["Kum, Elena"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-08-10T19:42:25Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chronic cough","Cough","Refractory Chronic Cough","Unexplained Chronic Cough"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33443","https://doi.org/10.71548/2227"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Refractory or unexplained chronic cough (RCC/UCC) is a debilitating condition that substantially impacts patients’ quality of life. No licensed therapies exist in Canada, and suboptimal clinical trial endpoints, coupled with large placebo responses, have hindered drug development. This thesis advances outcome measurement in RCC/UCC to improve the detection and interpretation of treatment effects. To characterize drug efficacy and placebo responses, we conducted a dose-response meta-analysis of gefapixant, the first P2X3 antagonist to reach phase 3 trials. This analysis quantified gefapixant’s modest efficacy and confirmed a substantial placebo response. To better understand this response and inform future trial designs, we described underlying neurobiological mechanisms as well as non-specific contributors, including regression-to-the-mean and patient expectancy. During review of the gefapixant development program, major regulatory agencies emphasized the need for outcome measures that better capture patient-important benefits and meet fit-for-purpose standards. We thus developed and evaluated the McMaster Cough Severity Questionnaire (MCSQ), an 8-item patient-reported outcome measure comprising two domains and a one-week recall period. Using mixed methods, classical test theory, and Rasch modelling, we demonstrated the MCSQ’s strong content validity, construct validity, and test-retest reliability, supporting its use as a promising endpoint for future clinical trials. To illustrate its application, we designed a 2x2 factorial randomized trial protocol evaluating the comparative effectiveness and harms of two commonly prescribed neuromodulators, low-dose morphine and pregabalin, and a non-pharmacologic intervention, cough control therapy, for RCC/UCC. This trial will further evaluate the MCSQ’s longitudinal validity, responsiveness, and minimal important differences. Collectively, this work strengthens the methodological foundation for clinical trials in RCC/UCC and supports more patient-centered evaluation of emerging therapies."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:title","label":"Title","values":["Advancing Outcome Measurement in Refractory or Unexplained Chronic Cough"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Satia, Imran"],"dc:contributor.department":["Health Research Methodology"],"dc:creator":["Kum, Elena"],"dc:date.accessioned":["2026-08-10T19:42:25Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Refractory or unexplained chronic cough (RCC/UCC) is a debilitating condition that substantially impacts patients’ quality of life. No licensed therapies exist in Canada, and suboptimal clinical trial endpoints, coupled with large placebo responses, have hindered drug development. This thesis advances outcome measurement in RCC/UCC to improve the detection and interpretation of treatment effects. To characterize drug efficacy and placebo responses, we conducted a dose-response meta-analysis of gefapixant, the first P2X3 antagonist to reach phase 3 trials. This analysis quantified gefapixant’s modest efficacy and confirmed a substantial placebo response. To better understand this response and inform future trial designs, we described underlying neurobiological mechanisms as well as non-specific contributors, including regression-to-the-mean and patient expectancy. During review of the gefapixant development program, major regulatory agencies emphasized the need for outcome measures that better capture patient-important benefits and meet fit-for-purpose standards. We thus developed and evaluated the McMaster Cough Severity Questionnaire (MCSQ), an 8-item patient-reported outcome measure comprising two domains and a one-week recall period. Using mixed methods, classical test theory, and Rasch modelling, we demonstrated the MCSQ’s strong content validity, construct validity, and test-retest reliability, supporting its use as a promising endpoint for future clinical trials. To illustrate its application, we designed a 2x2 factorial randomized trial protocol evaluating the comparative effectiveness and harms of two commonly prescribed neuromodulators, low-dose morphine and pregabalin, and a non-pharmacologic intervention, cough control therapy, for RCC/UCC. This trial will further evaluate the MCSQ’s longitudinal validity, responsiveness, and minimal important differences. Collectively, this work strengthens the methodological foundation for clinical trials in RCC/UCC and supports more patient-centered evaluation of emerging therapies."],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:identifier.uri":["https://hdl.handle.net/11375/33443","https://doi.org/10.71548/2227"],"dc:language.iso":["en"],"dc:subject":["Chronic cough","Cough","Refractory Chronic Cough","Unexplained Chronic Cough"],"dc:title":["Advancing Outcome Measurement in Refractory or Unexplained Chronic Cough"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:38:51Z"}